Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.
Search results for: hospital
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis
In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.
FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease
The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.
Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.
The Psychosocial Toll of COVID-19
Experts discussed the heavy toll the pandemic has taken on patients and clinicians, with many patients in need of mental health support and others in need of rehabilitation.
Smart, Stem Cell-Based Implants May Revolutionize the Treatment of Arthritis
Recent breakthroughs in stem cell-based treatments for arthritis may help delay joint replacement for some patients. Farshid Guilak, PhD, described the methods for creating bioartificial cartilage, its implications for inflammation, disease flare and more.
Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots
Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.
Denosumab Promising for Osteolysis after Total Hip Replacement
NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…
Risankizumab May Improve Symptoms of PsA
Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 330
- Next Page »